These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1358 related articles for article (PubMed ID: 25679074)
21. Clinical impact of Tuncel M; Kılıçkap S; Süslü N Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032 [TBL] [Abstract][Full Text] [Related]
22. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647 [TBL] [Abstract][Full Text] [Related]
23. The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer. Şahin E; Elboğa U J Med Imaging Radiat Oncol; 2020 Dec; 64(6):756-761. PubMed ID: 32656989 [TBL] [Abstract][Full Text] [Related]
24. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270 [TBL] [Abstract][Full Text] [Related]
25. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
26. Clinical utility of Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622 [TBL] [Abstract][Full Text] [Related]